U.S. Food and Drug Administration Extends Use of Appian BPM
Appian Named Business Process Management Vendor of Choice Under immixGroup Contract
RESTON, Va. & MCLEAN, Va.—September 27, 2010— Appian, the global innovator in enterprise and on-demand business process management (BPM) technology, and immixGroup, a leading provider of technology products and services to the public sector, today announced that the U.S. Food and Drug Administration (FDA) has extended its use of the Appian BPM Suite. FDA has chosen Appian as its BPM vendor of choice under a new five-year Blanket Purchase Agreement (BPA) with immixGroup. With all options, the contract value exceeds $12M.
Initially, the FDA conducted a competitive review and acquisition process to select a commercial Business Process Management System (BPMS) for a pilot program. Appian was selected for the pilot. As a result of the success of that program, the FDA extended the Appian platform, including technology licenses and support services, to four BPM projects. The new BPA is based on the success of those previous projects. Appian partnered with immixGroup to provide the BPA under immixGroup’s GSA Schedule.
Appian expects all FDA Centers will utilize the BPM platform as the FDA executes on its goal to better streamline and manage its core business processes. The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation. The FDA is also responsible for advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get the accurate, science-based information they need to use medicines and foods to improve their health.
“The extension of our relationship with the FDA strengthens Appian’s leadership position in BPM for the federal government,” said Matthew Calkins, president and CEO of Appian. “The federal market is the largest adopter of BPM technology because government agencies understand that the efficiency, transparency, accountability and collaboration benefits of BPM directly support the current administration’s mandates for how government needs to operate.”
“immixGroup is focused on bridging the gap between government and technology vendors, making leading commercial technology more accessible to the public sector,” said Art Richer, president of immixGroup. “This BPA makes it easier than ever before for FDA customers to acquire the Appian BPM technology they need to accomplish their missions.”
About immixGroup, Inc.
immixGroup brings commercial technology products and services to the public sector. Since 1997, immixGroup has helped hundreds of companies—including IBM, Oracle, EMC, and McAfee—grow and manage their government business while providing federal, state, and local agencies with reliable access to leading commercial technologies. immixGroup is a recognized leader in the public sector technology marketplace, with four divisions delivering a unique combination of services. These include technology sales via preferred contract vehicles, innovative government channel programs, expert contract management consulting, and outsourced IT solutions. For more information, contact immixGroup, Inc. at 703.752.0610, via email at email@example.com, or on the Web at http://www.immixgroup.com.
Appian delivers an enterprise platform for digital transformation that enables organizations to revolutionize their customer experience, optimize their business operations, and master global risk and compliance. Powered by industry leading Business Process Management (BPM) and Case Management capabilities, Appian’s low-code approach radically accelerates the time it takes to build and deploy powerful, modern applications, on-premises or in the cloud. For more information, visit www.appian.com.